Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ally Bridge Group
BioCentury | Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
BioCentury | May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | May 3, 2024
Finance
Public equity report: Soleno, Abeona raise capital for late-stage rare disease programs
Plus a $100M PIPE for cancer play Context Therapeutics
BioCentury | Apr 3, 2024
Deals
With $1.8B ProfoundBio deal, Genmab gains chance to market ‘100% owned’ product
Along with ADC platform, the Danish antibody specialist gains a FOLR1-targeting product entering pivotal testing for ovarian cancer
BioCentury | Mar 5, 2024
Management Tracks
Promotions at Ally Bridge
Plus: Schreyer named CTO at Anagenex, and updates from 4M, Sitryx and Apollomics
BioCentury | Feb 16, 2024
Finance
Venture report: Earlybird’s €173M fund, launches for Firefly and Latigo
European VC closes new vehicle; start-ups backed by Versant, Westlake Village out of stealth; Medicxi’s bundle; rounds for Freenome, ProfoundBio
BioCentury | Jan 4, 2024
Finance
Jan. 3 Quick Takes: Goldman Sachs unveils $650M life sciences fund
Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo
BioCentury | Dec 7, 2023
Emerging Company Profile
GenFleet: building a fleet of first-in-class cancer and immune therapies
With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapies
BioCentury | Oct 23, 2023
Deals
Oct. 23 Quick Takes: Merck drops two Kelun ADCs
Plus: FDA guidance facilitates communication about off-label uses and updates from Verve, Celltrion, Sanofi, Regeneron, Revolution, Harpoon, Aligos
BioCentury | Aug 2, 2023
Finance
Aug. 2 Quick Takes: CG Oncology raises $105M crossover round
Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more
Items per page:
1 - 10 of 120